Latest Breaking News On - Across patient populations - Page 1 : vimarsana.com

AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress

AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

Chiedzo mpofuUpadacitinib spondyloarthritisGlobal medical affairsAbbvie ltdStandard laboratoryUnited rheumatology normalized integrated community evidenceBoehringer ingelheimEuropean unionAbbvie incAbbvie deutschland gmbh coAssociation between clinically meaningful improvements in patientGroup analysisExchange commissionEuropean alliance of associationsImpact of risankizumab on improving healthEuropean alliance

AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesUpadacitinib monotherapyBrandee pappalardoAmerican college of rheumatologyRheumatology patient research registryAbbvie incDrug administrationAssociation between clinically meaningful improvements in patientEuropean commissionGroup analysisAssociation between clinically meaningful back pain improvementLaboratory abnormality profiles of upadacitinibExchange commissionAmerican collegeTerm safetyRheumatoid arthritis

AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021

ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing .

United statesUpadacitinib monotherapyBrandee pappalardoAmerican college of rheumatologyRheumatology patient research registryAbbvie incDrug administrationAssociation between clinically meaningful improvements in patientEuropean commissionGroup analysisAssociation between clinically meaningful back pain improvementLaboratory abnormality profiles of upadacitinibExchange commissionAmerican collegeTerm safetyRheumatoid arthritis

AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021

/PRNewswire/ AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab).

Upadacitinib monotherapyRheumatology patient research registryAssociation between clinically meaningful improvements in patientAssociation between clinically meaningful back pain improvementGroup analysisLaboratory abnormality profiles of upadacitinibTerm safetyRheumatoid arthritisCombination therapyAcross patient populationsResponse between upadacitinibResults throughSerologic statusClinical responsesPrior inadequate responseSub group analysis